Category: Latest News
-

RXO Shares Rise After C.H. Robinson Agrees $5.8 Billion Acquisition
RXO Inc. (NYSE:RXO) shares rose more than 18.5% in pre-market trading on Monday after C.H. Robinson Worldwide Inc. (NASDAQ:CHRW) agreed to acquire the transportation services company in a cash-and-stock transaction valued at $5.8 billion. Under the agreement, RXO shareholders will receive $17.25 in cash and 0.0856 C.H. Robinson shares for each RXO share held, representing…
-

Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial
Vaxcyte, Inc. (NASDAQ:PCVX) shares rose 50% on Monday after the company reported topline results from its pivotal OPUS-1 Phase 3 trial evaluating VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. VAX-31 met all prespecified primary endpoints across the age groups studied in comparisons with Prevnar 20 and Capvaxive. In adults aged 50 and older, the vaccine…
-

CME Group Plans Futures Contracts for AI Computing Capacity
CME Group (NASDAQ:CME) plans to introduce futures contracts linked to artificial intelligence computing capacity, creating a standardised derivatives product based on the cost of renting AI processing power. The exchange announced the planned contracts in August. Pete Keavey, the CME executive responsible for the initiative, said the aim is to standardise compute trading in a…
-

Vertical Aerospace Appoints Former Leonardo Helicopters US CEO to Board
Vertical Aerospace (NYSE:EVTL) has appointed Clyde M. Woltman to its Board of Directors, effective October 5, 2026. Woltman previously served as chief executive of Leonardo Helicopters US, where he oversaw a $1 billion business covering sales, engineering, certification, production, customer support and research and development across the Americas. His responsibilities also included US Government and…
-

FDA Extends Review of Novo Nordisk Haemophilia A Treatment Denecimig
Novo Nordisk (NYSE:NVO) said the US Food and Drug Administration has extended its review of denecimig, the company’s treatment for haemophilia A, due to ongoing remediation activities at its manufacturing facility. The company submitted a Biologics License Application for denecimig in September 2025 for the treatment of adults and children with haemophilia A, with or…
-

Tutor Perini Unit Awarded $315 Million US Coast Guard Fuel Pier Contract
Tutor Perini Corporation (NYSE:TPC) said its subsidiary Perini Management Services has been awarded a contract worth approximately $315 million by the US Coast Guard for a new fuel pier at Coast Guard Base Kodiak in Alaska. The project will use an accelerated design-build-to-budget delivery method and is intended to expand dock capacity at the base…
-

GE Vernova Customers Receive Three 2026 POWER Magazine Awards
Several GE Vernova (NYSE:GEV) customers received recognition in the 2026 POWER Awards for power generation projects using the company’s technologies. The annual awards programme, organised by POWER Magazine, recognises projects and performance across the electricity generation industry. PetroVietnam Power Corporation’s Nhon Trach 3&4 Power Plant in Vietnam received both the Plant of the Year Award…
-

Autodesk Shares Rise Following Schneider Electric’s $22.6 Billion PTC Deal
Autodesk (NASDAQ:ADSK) shares rose 3.8% in pre-market trading after Schneider Electric announced an agreement to acquire PTC for $22.6 billion in cash. Under the transaction, Schneider Electric will acquire PTC, a provider of industrial design and product lifecycle management software, at a 42.3% premium to its previous closing share price. The acquisition is Schneider Electric’s…
-

Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
Zentalis Pharmaceuticals (NASDAQ:ZNTL) shares rose 4.4% in pre-market trading after Leerink Partners assumed coverage of the biotechnology company with an Outperform rating and an $8 price target. The rating compares with Leerink’s previous Market Perform recommendation and $4 price target. Leerink’s assessment focuses on Zentalis’ lead oncology candidate azenosertib, an investigational WEE1 inhibitor being developed…
-

Leslie’s Shares Fall Ahead of Nasdaq Trading Suspension
Leslie’s (NASDAQ:LESL) shares fell 23.1% in pre-market trading to $0.112 ahead of the scheduled suspension of trading in the pool and spa care retailer’s stock at the opening of business on October 6, 2026. Nasdaq notified Leslie’s on September 25 that its shares were subject to delisting after the closing bid price remained below the…